Press Release   -

Global In Vitro Fertilization (IVF) Market Set to Surge to USD 63.7 Billion by 2035

The fertility industry is entering a transformative phase as In Vitro Fertilization (IVF) becomes an increasingly central pillar in reproductive health solutions worldwide. A new report from Vantage Market Research reveals that the global IVF market is estimated to reach USD 28.12 billion in 2024 and is forecasted to nearly double to USD 63.7 billion by 2035, with a robust CAGR of 7.75% over 2025–2035. This press release outlines the report’s key takeaways, segmentation insights, regional outlook, competitive landscape, recent developments, and the dynamics shaping growth in this critical healthcare sector.

Key Takeaways

1. The global IVF market is projected to grow from USD 28.12 billion in 2024 to USD 63.7 billion by 2035, representing a CAGR of 7.75%
2. Asia Pacific leads both in current size and fastest growth trajectory among regions
3. Key product categories include Equipment, Reagents & Media, and Accessories
4. Among cycle types, Fresh Non-donor, Frozen Non-donor, Frozen Donor, and Fresh Donor cycles are major sub-segments
5. Major players in the IVF ecosystem include The Cooper Companies, Cook Group, Vitrolife, Thermo Fisher Scientific, Esco Micro, Genea, IVFtech, Fujifilm Irvine Scientific, The Baker Company, Kitazato, Rocket Medical, Hamilton Thorne, ZEISS, Fertipro NV, and Gynotec

Key Market Trends & Insights

1. Rising infertility rates associated with delayed parenthood, lifestyle factors, and reproductive health challenges are fueling demand for IVF services globally.
2. Technological advancements including AI-driven embryo selection, improved culture media, time-lapse imaging, and lab automation are improving success rates and operational efficiency.
3. Expansion of fertility clinics, especially in emerging markets, and growing medical tourism for IVF procedures are boosting regional growth.
4. However, high procedure costs, variability in regulatory reimbursements, and ethical/safety concerns (e.g. embryo mix-ups) pose restraints.

Market Size & Forecast

1. 2024 Revenue Estimate: USD 28.12 billion (base year)
2. 2035 Forecast: USD 63.7 billion
3. CAGR (2025–2035): 7.75%

The global IVF market is moderately consolidated dominated by a handful of major players with strong R&D capabilities, established distribution networks, and clinic partnerships. According to Vantage, leading OEMs and suppliers such as Cooper, Cook, Thermo Fisher, and Vitrolife capture significant share of high-end equipment and consumables. However, the market exhibits segmentation by region, clinic scale, and product specialization (e.g. AI-based platforms, niche culture media), permitting room for mid-tier innovators and specialized providers. Emerging regions may offer lower barriers to entry for local participants, especially in reproductive services, though regulatory and quality constraints remain critical.

Product Insights

The In Vitro Fertilization (IVF) market, as per Vantage Market Research, is segmented into Equipment, Reagents & Media, and Accessories. Equipment such as incubators, imaging systems, and micromanipulators account for the highest revenue share due to their essential role in IVF laboratories. Reagents & Media form the backbone of the fertilization and embryo culture process, generating consistent recurring revenue. Accessories, including labware and disposables, offer a steady market segment driven by the high turnover rate in clinical settings.

Cycle Insights

Vantage segments the IVF market by Fresh Non-Donor, Frozen Non-Donor, Fresh Donor, and Frozen Donor cycles. Fresh Non-Donor cycles currently dominate due to their well-established protocols and higher success rates in some patient profiles. However, Frozen Non-Donor cycles are rapidly gaining traction as cryopreservation technology improves embryo viability. Donor cycles serve couples with low fertility potential or genetic risks, contributing smaller but growing shares as donor programs expand globally and social acceptance increases.

Type Insights

Based on Type, the market includes Conventional IVF, IVF with Intracytoplasmic Sperm Injection (ICSI), IVF with Donor Eggs, and Others. Conventional IVF remains widely used, though ICSI has gained significant momentum due to its enhanced fertilization efficiency, particularly in male infertility cases. IVF with Donor Eggs serves women with reduced ovarian reserve, while Other types, including AI-assisted IVF or pre-implantation genetic testing (PGT), reflect the market’s move toward personalization and higher success outcomes through precision reproductive medicine.

End User Insights

The market by End User includes Fertility Clinics, Hospitals & Surgical Centers, Cryobanks, and Research Institutes. Fertility Clinics dominate the market, accounting for the majority of IVF cycle volumes, owing to their specialized expertise and integrated facilities. Hospitals & Surgical Centers support complex reproductive surgeries and embryo retrieval procedures. Cryobanks contribute by offering long-term storage solutions for gametes and embryos. Meanwhile, Research Institutes drive innovation through studies on embryo quality, reproductive genetics, and advanced fertility techniques.

Regional Insights

North America IVF Market Trends

The North American IVF market is characterized by high awareness, advanced healthcare infrastructure, and relatively favorable reimbursement environments. In the U.S. specifically, the IVF market is valued at USD 5.76 billion in 2024 and is expected to reach USD 10.7 billion by 2035, representing a CAGR of 5.8%. Technological leadership (AI, genetic testing), strong clinic networks, and regulatory support bolster growth. However, cost barriers and insurance coverage gaps still limit patient access, prompting cross-state treatment or fertility benefit firms to step in.

Europe IVF Market Trends

Europe represents a well-established IVF hub with strong clinical expertise, high regulatory standards, and public funding initiatives in several countries. Nations such as the UK, Spain, Germany, and Denmark lead in treatment volume and innovation. The region benefits from a robust fertility tourism market, particularly in countries with liberal donor regulations. However, differences in government reimbursement and eligibility criteria across the EU create uneven market penetration. Overall, Europe remains a key global contributor to IVF procedure advancements.

Asia Pacific IVF Market Trends

Asia Pacific dominates the global IVF market in both volume and growth rate, according to Vantage Market Research. Factors such as a large reproductive-age population, growing infertility prevalence, rising disposable incomes, and government support for fertility treatments drive regional growth. Countries including China, India, Japan, and South Korea are major contributors. Rapid adoption of advanced reproductive technologies and expansion of fertility clinics make Asia Pacific a hotspot for IVF medical tourism, boosting accessibility and affordability across diverse demographics.

Latin America IVF Market Trends

The Latin American IVF market is gradually expanding due to improving awareness, urbanization, and the increasing number of private fertility centers. Countries such as Brazil, Mexico, and Argentina are leading in IVF adoption. While public healthcare systems still offer limited IVF coverage, growing middle-class income and supportive government reforms are enhancing market potential. Fertility tourism from North America also contributes to demand. However, limited access in rural areas and varying regulatory frameworks continue to restrain widespread adoption.

Middle East & Africa IVF Market Trends

The Middle East & Africa region presents mixed market maturity. Gulf Cooperation Council (GCC) countries such as the UAE, Saudi Arabia, and Qatar are witnessing strong IVF growth due to rising infertility rates and significant healthcare investments. Advanced clinics attract patients from Africa and neighboring regions seeking affordable, high-quality treatments. In contrast, most African nations still face limited access to reproductive care due to infrastructure and affordability challenges. Over time, improving awareness and liberalizing fertility policies are expected to foster regional growth.

Top Key Players

1. The Cooper Companies Inc.
2. Cook Group
3. Vitrolife
4. Thermo Fisher Scientific Inc.
5. Esco Micro PTE. Ltd.
6. Genea Limited
7. IVFtech ApS
8. FUJIFILM Irvine Scientific
9. The Baker Company Inc.
10. Kitazato Corporation
11. Rocket Medical plc
12. Hamilton Thorne Ltd.
13. ZEISS Group

These firms span the spectrum of IVF lab equipment, consumables, media, and support technologies. Many also engage in strategic partnerships with clinics, invest in AI/automation, or supply end-to-end IVF lab systems.

Recent Developments

1. In 2024–2025, Monash IVF in Australia came under scrutiny after a reported embryo mix-up led to the birth of a child from another patient’s embryo. This incident brought renewed attention to error-prevention, regulation, and quality assurance in IVF labs.
2. A Georgia couple filed a lawsuit against CooperSurgical for a defective culture media product that allegedly destroyed 16 embryos, highlighting vulnerabilities in consumables and regulatory oversight.
3. Poland’s liberal government reinstated public IVF funding beginning mid-2024, resulting in a surge of fertility treatments over 9,200 pregnancies by early 2025, signaling how policy shifts can rapidly influence market uptake.
4. A notable restructuring occurred at Fertilis (Australia) in mid-2024: after accumulating losses, creditors approved an injection of capital to salvage the company, ensuring continued commercialization of its micro-IVF device.

In Vitro Fertilization Market Report Scope

This press release is based primarily on the Vantage Market Research “In Vitro Fertilization Market” report (industry-report/in-vitro-fertilization-market-1649) covering the period 2024 (base year) through 2035 (forecast). The report deeply segments the market by Product (Equipment, Reagents & Media, Accessories), Cycle Type, End-User, and Region. It provides quantitative forecasts (revenue), qualitative insights, profiles of key players, trend analysis, driver/ restraint/opportunity assessments, and strategic implications.

Market Dynamics

Driver

The primary growth driver is escalating infertility rates globally, fueled by delayed parenthood, lifestyle factors, and reproductive health challenges. This growing unmet need for fertility interventions supports strong demand for IVF solutions.

Restraint

High costs of IVF procedures, limited insurance or government reimbursement in many regions, and regulatory hurdles (e.g. embryo rights, donor rules) continue to restrict adoption, especially in underdeveloped markets.

Opportunity

Technological innovations such as AI-enabled embryo assessment, non-invasive genetic testing, lab automation, and predictive analytics — offer opportunities to improve outcomes, reduce cycle times, and lower costs, opening new market segments.

Challenges

Maintaining quality control and safety (e.g. addressing embryo mix-up risks), navigating complex regulatory and ethical landscapes, and bridging access affordability gaps are persistent challenges. Competition from emerging local players and regulatory scrutiny add pressure to incumbents.

Market Segmentation

1. By Product: Equipment / Reagents & Media / Accessories
2. By Cycle: Fresh Non-Donor / Frozen Non-Donor / Frozen Donor / Fresh Donor
3. By Type: Conventional IVF / IVF with ICSI / IVF with Donor Eggs / Others
4. By End-User: Fertility Clinics / Hospitals & Surgical Centers / Cryobanks / Research Institutes
5. By Region: North America / Europe / Asia Pacific / Latin America / Middle East & Africa

Frequently Asked Questions

Q. What is the size of the IVF market in 2024?

A. According to Vantage, USD 28.12 billion.

Q. What is the forecast for 2035?

A. USD 63.7 billion per Vantage’s projection.

Q. What CAGR is expected over 2025–2035?

A. 7.75% CAGR as per Vantage.

Q. Who are the key players in this market?

A. The Cooper Companies, Cook Group, Vitrolife, Thermo Fisher Scientific, Esco Micro, Genea, IVFtech, Fujifilm Irvine Scientific, The Baker Company, Kitazato, Rocket Medical plc, Hamilton Thorne, ZEISS, Fertipro NV, and Gynotec.

Q. What are the major growth drivers and restraints?

A. Drivers include rising infertility, technological advances, and clinic expansion; restraints include cost, reimbursement, regulatory constraints, and safety risks.